Carbinoxamine Maleate

Check Drug InteractionsCheck known drug interactions.

Check Drug Interactions

Carbinoxamine Maleate Prescribing Information

Carbinoxamine maleate is effective for the symptomatic treatment of:

Seasonal and perennial allergic rhinitis.

Vasomotor rhinitis.

Allergic conjunctivitis due to inhalant allergens and foods.

Mild, uncomplicated allergic skin manifestations of urticaria and angio-edema.

Dermatographism.

As therapy for anaphylactic reactions

adjunctive

to epinephrine and other standard measures after the acute manifestations have been controlled.

Amelioration of the severity of allergic reactions to blood or plasma.

Carbinoxamine maleate is contraindicated in children younger than 2 years of age (see CONTRAINDICATIONS).

Carbinoxamine maleate should be taken on an empty stomach with water.

DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT.

Carbinoxamine maleate dosage should bebased on the severity of the condition and the response of the patient. The drug is well tolerated in adults in doses as high as 24 mg daily, in divided doses, over prolonged periods. On the other hand, some patients respond to as little as 4 mg daily.

Clinical experience suggests the followingdosage schedules:

Tablets

Usual Adult Dosage:

1 or 2 tablets (4 to 8 mg)

3 to 4 times daily.

Usual Child’s Dosage:

Six to eleven years – ½ to 1 tablet

(2 to 4 mg) 3 to 4 times daily.

The most frequent adverse reactions are underlined:

Body as a Whole:

Urticaria, drug rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dryness of mouth, nose and throat.

Cardiovascular:

Hypotension, headache, palpitations, tachycardia, extrasystoles.

Hematologic:

Hemolytic anemia, thrombocytopenia, agranulocytosis.

Central Nervous System:

Sedation, sleepiness, dizziness, disturbed coordination,

fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, hysteria, neuritis, convulsions.

Gastrointestinal:

Epigastric distress,

anorexia, nausea, vomiting, diarrhea, constipation.

Urogenital:

Urinary frequency, difficult urination, urinary retention, early menses.

Respiratory:

Thickening of bronchial secretions,

tightness of chest and wheezing, nasal stuffiness.

To report SUSPECTED ADVERSE REACTIONS, contact BioComp Pharma, Inc. at 1-866-762-2365 or FDA at 1-800-FDA-1088 or

www.fda.gov/medwatch

Carbinoxamine maleate is a histamine-H1 receptor blocking agent.

Each tablet contains 4 mg carbinoxamine maleate and the following inactive ingredients: anhydrous lactose, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate.

Carbinoxamine maleate is freely soluble in water. Its structure is:

2-[(4-chlorophenyl)-2-pyridinylmethoxy]-

, N-

dimethylethanamine

(Z)-2-butenedioate (1:1)

C
₁₆H
₁₉CIN
₂O•C
₄H
₄O
₄

MW=406.86

Report Adverse Event

Carbinoxamine Maleate

Carbinoxamine Maleate Prescribing Information

Carbinoxamine Maleate PubMed™ News